211513-21-2

Usage

Uses

Used in Pharmaceutical Industry:
1-(2-Ethylbutyl)-N-(2-sulfanylphenyl)cyclohexanecarboxamide is used as a potential pharmaceutical compound for its possible wide range of biological activities. The presence of the carboxamide group and the sulfanylphenyl group may contribute to its reactivity and pharmacological properties, making it a candidate for further research and development in drug discovery and therapeutic applications.
Used in Drug Discovery:
1-(2-Ethylbutyl)-N-(2-sulfanylphenyl)cyclohexanecarboxamide is used as a candidate molecule in drug discovery due to its unique structural features and the potential for various biological activities. 1-(2-Ethylbutyl)-N-(2-sulfanylphenyl)cyclohexanecarboxaMide's structure may allow for modifications and optimizations to enhance its therapeutic potential and target specific diseases or conditions.
Used in Research and Development:
1-(2-Ethylbutyl)-N-(2-sulfanylphenyl)cyclohexanecarboxamide is used as a subject of research and development to better understand its properties, reactivity, and potential applications. 1-(2-Ethylbutyl)-N-(2-sulfanylphenyl)cyclohexanecarboxaMide's structure and the presence of functional groups like the carboxamide and sulfanylphenyl groups make it an interesting target for scientific investigation and potential pharmaceutical applications.

InChI:InChI=1/C19H29NOS/c1-3-15(4-2)14-19(12-8-5-9-13-19)18(21)20-16-10-6-7-11-17(16)22/h6-7,10-11,15,22H,3-5,8-9,12-14H2,1-2H3,(H,20,21)

Upstream product

• 98-89-5 Cyclohexanecarboxylic acid 
• 211513-15-4 bis-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]disulfide 
• 211515-46-7 1-(2-ethyl-butyl)-cyclohexanecarbonyl chloride 
• 3814-34-4 2-ethyl-1-bromobutane 
• 381209-09-2 1-(2-ethyl-butyl)-cyclohexanecarboxylic acid 

Downstream Products

• 211513-37-0 dalcetrapib 

Relevant academic research and scientific papers

New Process

The present invention relates to a process for the preparation of S-[2-[1-(2-ethylbutyl)cyclohexylcarbonylamino]-phenyl]2-methylthiopropionate which is useful as a pharmaceutically active compound.

CETP activity inhibitors

The present invention provides a CETP activity inhibitor comprising as an active ingredient a compound represented by the formula (I): wherein R represents a straight chain or branched alkyl group; a straight chain or branched alkenyl group; a lower haloalkyl group; a substituted or unsubstituted cycloalkyl group; a substituted or unsubstituted cycloalkenyl group; a substituted or unsubstituted cycloalkylalkyl group; a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group, X1, X2, X3, and X4may be the same or different and each represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower haloalkyl group; a lower alkoxy group; a cyano group; a nitro group; an acyl group; or an aryl group, Y represents —CO— or —SO2—, and Z represents a hydrogen atom or a mercapto-protecting group, or a prodrug compound, a pharmaceutically acceptable salt, or hydrate or solvate thereof. The compounds represented by the formula (I) can increase HDL and at the same time decrease LDL through selective inhibition of CETP activity and, therefore, is expected to be useful as a new type of a preventive or therapeutic agent for atherosclerosis or hyperlipidemia.

Bis(2-(acylamino)phenyl) disulfides, 2-(acylamino)benzenethiols, and S-(2-(acylamino)phenyl) alkanethioates as novel inhibitors of cholesteryl ester transfer protein

A series of bis(2-(acylamino)phenyl) disulfides, 2-(acylamino)benzenethiols, S-(2-(acylamino)-phenyl) alkanethioates, and related compounds were synthesized, and their inhibitory effect on cholesteryl ester transfer protein activity in human plasma was evaluated. This study elucidated the structural requirements for inhibitory activity and determined that the optimum compound was S-(2-((1-(2-ethylbutyl)cyclohexane)carbonylamino)phenyl) 2-methylpropanethioate (27) (JTT-705). This compound achieved 50% inhibition of CETP activity in human plasma at a concentration of 9 μM and 95% inhibition of CETP activity in male Japanese white rabbits at an oral dose of 30 mg/kg. It increased the plasma HDL cholesterol level by 27% and 54%, respectively, when given at oral doses of 30 or 100 mg/kg once a day for 3 days to male Japanese white rabbits.